In the published article, there was an error in Table 4 as published. The target for metyrapone was listed twice while the target for lomibuvir was missed. The corrected Table 4 and its caption [Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose] appear below.
Table 4
| Compound | Potential binding viral targets | Docking score | Binding energy (kcal/mol) | Ligand Efficiency (kcal/ mol) | |
|---|---|---|---|---|---|
| 2-Fluroadenine |  |  | (a)-6.966 (b)-2.958 | -37.69 -25.51 | -11.091 -5.632 |
| Doxorubicin |  |  | (a)-4.76 (b)-6.069 (c)-3.547 | -77.88 -77.55 -77.21 | -13.179 -15.343 -13.297 |
 | |||||
| Felbiac |  |  | (a)-4.332 (b)-6.115 | -44.3 -39.72 | -11.74 -10.529 |
| Metyrapone |  |  | (a)-4.358 (b)-6.498 | -51.12 -50.81 | -12.521 -13.255 |
| Enalprilat |  |  | (a)-7.476 (b)-4.02 | -60.97 -55.33 | -14.452 -11.234 |
| Emetine |  |  | (a)-4.086 (b)-4.238 | -74.25 -71.81 | |
| Resveratrol |  |  | (a)-6.22 (b)-4.675 | -56.45 -47.43 | -14.72 -11.734 |
| Lombubivir |  |  | (a)-5.573 (b)-4.759 | -81.13 -78.83 | |
Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
chikungunya virus (CHIKV), drug repurposing, structural and non-structural proteins, in silico screening, in vitro validation
Citation
Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, Alagarasu K, Parashar D and Cherian S (2023) Corrigendum: Drug repurposing approach against chikungunya virus: an in vitro and in silico study. Front. Cell. Infect. Microbiol. 13:1226054. doi: 10.3389/fcimb.2023.1226054
Received
20 May 2023
Accepted
22 May 2023
Published
23 June 2023
Volume
13 - 2023
Edited and reviewed by
Daniel Salamango, Stony Brook University, United States
Updates
Copyright
© 2023 Kasabe, Ahire, Patil, Punekar, Davuluri, Kakade, Alagarasu, Parashar and Cherian.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Deepti Parashar, deeptiparasharster@gmail.com; Sarah Cherian, sarahcherian100@gmail.com
†These authors have equally contributed to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.